Early Detection and Management of Bronchiolitis Obliterans Syndrome Following Pediatric Hematopoietic Stem Cell Transplantation

NCT03072849 COMPLETED

This study aims to determine whether or not early spirometric detection and management of obstructive lung disease with combined fluticasone/azithromycin/montelukast therapy (FAM) can attenuate declining lung function, prevent the development of bronchiolitis obliterans, and improve patient outcomes following hematopoietic stem cell transplant.

Details

Lead sponsor	Ann & Robert H Lurie Children's Hospital of Chicago
Status	COMPLETED
Enrolment	23
Start date	2015-04
Completion	2020-09-01

Conditions

• Bronchiolitis Obliterans Syndrome

Interventions

• Pulmonary function testing
• FAM Therapy

Primary outcomes

• Lung function — 2 years
  Change in lung function at 12 and 24 months post-HSCT
• Survival — 2-4 years
  Overall survival at 2 years post-HSCT

Countries

United States